Integrin Alpha10-Selected MSCs for ARDS Treatment
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for acute respiratory distress syndrome (ARDS) are limited in effectively targeting inflammatory mechanisms and reducing mortality, with existing pharmacologic therapies failing to address disease-specific pathways effectively.
Innovation Solution
The use of integrin alpha10-selected mesenchymal stem cells (MSCs), which exhibit immunomodulatory and anti-inflammatory properties, to improve hemodynamic stability, reduce blood clot formation, and minimize lung tissue damage in ARDS models.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If pharmacologic therapy targets specific molecules or pathways in ARDS, then the treatment should address inflammatory mechanisms, but existing drugs have failed to effectively reduce mortality or act on disease-specific pathways
Solution Approach 1:
The patent uses mesenchymal stem cells (MSCs) as intermediary cells that mediate the therapeutic effect by modulating the immune response and reducing inflammation. These cells act as biological mediators that interact with the complex inflammatory pathways in ARDS, providing a more effective treatment approach than direct pharmacologic intervention on specific molecules.
Solution Approach 2:
The invention changes the fundamental parameter of treatment from chemical pharmacologic agents to biological cellular therapy. By using MSCs with specific immunomodulatory properties, the treatment approach shifts from targeting specific inflammatory molecules to using living cells that can dynamically adapt and modulate the inflammatory response through multiple mechanisms simultaneously.
2Reliability
If supportive care strategies are used to preserve respiratory exchange, then patient survival is maintained, but these strategies do not represent real treatment of the underlying inflammatory disease
Solution Approach 1:
The patent applies preliminary action by administering MSCs early in the disease course to prevent further inflammatory damage before irreversible lung injury occurs. The cells are given prophylactically to modulate the immune response and protect lung tissue, rather than waiting for severe damage to occur and then attempting treatment.
Solution Approach 2:
MSCs serve as biological intermediaries that bridge the gap between supportive care and active disease treatment. These cells actively modulate the inflammatory response while patients receive continued supportive care, providing a dual approach that both treats the underlying disease and maintains respiratory function.
3Reliability
If MSCs are selected based on integrin alpha10 expression, then immunomodulatory and anti-inflammatory properties are enhanced, but cell selection complexity increases
Solution Approach 1:
The patent applies local quality by selecting MSCs with specific integrin alpha10 surface expression characteristics. This creates a heterogeneous cell population with varying degrees of immunomodulatory activity, where cells with higher integrin alpha10 expression provide stronger anti-inflammatory effects. The selection is based on a specific local property (surface marker expression) rather than requiring complex genetic or functional screening.
Data Source
AI summary
The present invention concerns the use of integrin alpha10-selected mesenchymal stem cells for treatment of respiratory tract disorders, diseases and trauma affecting the respiratory tract.